Key Highlights
- License Revenue was USD 1.26 million, compared with USD 784 thousand.
- Net income was USD 491 thousand, compared with USD 152 thousand.
- Earnings per share were USD 0.04, compared with USD 0.01.
- Cash and cash equivalents were USD 10.45 million at September 30, 2026.
TherapeuticsMD (NASDAQ:TXMD) reported license revenue of USD 1.26 million for the third quarter of 2026, compared with USD 784 thousand in the prior-year quarter. Net Income was USD 491 thousand, compared with USD 152 thousand, and basic and diluted net income per common share was USD 0.04, compared with USD 0.01.
For the nine months ended September 30, 2026, license revenue was USD 2.85 million, compared with USD 2.13 million, and net income was USD 741 thousand, compared with USD 50 thousand.
Operating Results
General and administrative expenses were USD 1.64 million, compared with USD 1.52 million, and Depreciation and amortization was USD 97 thousand, compared with USD 96 thousand. Total operating expenses were USD 1.74 million, compared with USD 1.65 million, and the loss from operations was USD 479 thousand, compared with USD 862 thousand.
Other income, net, was USD 980 thousand, compared with USD 912 thousand. It included interest income, net, of USD 77 thousand, sublease income of USD 521 thousand and miscellaneous income of USD 382 thousand.
Nine-Month Results
Total operating expenses for the nine months were USD 4.87 million, compared with USD 4.97 million, and the loss from operations was USD 2.02 million, compared with USD 2.84 million. Other income, net, was USD 2.79 million, compared with USD 2.77 million. Net income per common share for the nine months was USD 0.06. Weighted average basic common shares outstanding were 11,574 thousand.
Balance Sheet and Royalty Agreement
Cash and cash equivalents were USD 10.45 million at September 30, 2026, compared with USD 7.48 million at December 31, 2025. The current portion of the royalty receivable was USD 3.41 million, compared with USD 3.53 million, and total current Assets were USD 17.42 million, compared with USD 14.45 million. Total assets were USD 37.93 million, compared with USD 37.66 million, and total liabilities were USD 10.31 million, compared with USD 10.78 million.
The filing states that in December 2022 the company changed its Business to become a pharmaceutical royalty company. Under the Mayne License Agreement, Mayne Pharma agreed to pay royalties on net sales of all products in the United States at a rate of 8.0% on the first USD 80.0 million in annual net sales and 7.5% on annual net sales above USD 80.0 million for 20 years following the closing date, and to pay minimum annual royalties of USD 3.0 million per year for 12 years.
The filing states that the royalty rate decreases to 2.0% on a product-by-product basis upon the earlier of the expiration or revocation of the last Patent covering a product and the launch of a generic version of a product in the United States. Upon the expiry of the 20-year royalty term, the licenses granted to Mayne Pharma become fully paid-up and royalty free. Mayne Pharma also agreed to pay approximately USD 1.0 million in prepaid royalties on the closing date of the amendment.
TherapeuticsMD Q3 2026 Earnings: Key Takeaways
TherapeuticsMD reported third quarter 2026 license revenue of USD 1.26 million and net income of USD 491 thousand. Cash and cash equivalents were USD 10.45 million at September 30, 2026.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...